Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an observational study to compare the effectiveness of dual therapy of Type II diabetes mellitus with metformin + sitagliptin versus metformin + a sulfonylurea in routine clinical practice in France.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Metformin + Sitagliptin | Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice. |
| |
| Metformin + Sulfonylurea | Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride. |
| |
| Sitagliptin +/- Other Antihyperglycemic Medication | Participants taking sitagliptin +/- other antihyperglycemic medication (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Metformin | Drug |
| ||
| Sitagliptin |
| Measure | Description | Time Frame |
|---|---|---|
| Median Duration (in Months) of Initial Dual Therapy | The treatment maintenance duration corresponds to the treatment maintenance and persistence duration for dual therapy combining the same agents. Withdrawal of an agent, replacement of one agent by another or addition of a third agent is perceived as a change in treatment and, hence, the end of the treatment maintenance duration for dual therapy. | Up to 3 years |
| Percentage of Participants With Strict Changes in Initial Dual Therapy | Strict changes in dual therapy were defined as withdrawal of an agent, replacement of one agent by another, or the addition of a third agent. Changes in dose level were not considered strict changes. | Up to 3 years |
Not provided
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Participants with type II diabetes mellitus receiving a de novo prescription (for the first time or within less than 8 weeks) for dual therapy with or without Januvia®/Xelevia® or any other treatment regimen including Januvia®/Xelevia® by general practitioners in private practice under real life conditions without any additional treatment or monitoring procedures.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25976701 | Result | Valensi P, de Pouvourville G, Benard N, Chanut-Vogel C, Kempf C, Eymard E, Moisan C, Dallongeville J. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study. Diabetes Metab. 2015 Jun;41(3):231-8. doi: 10.1016/j.diabet.2015.03.007. Epub 2015 May 12. |
Not provided
| ID | Type | URL | Comment |
|---|---|---|---|
| CSR Synopsis | View IPD |
Not provided
This was an observational, non-randomized, prospective, longitudinal study of participants with Type 2 diabetes mellitus treated in routine clinical practice by 1,569 primary care practitioners in metropolitan France. Study participants were enrolled from July 29, 2009 to December 31, 2010. The end of study follow-up was August 31, 2013.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Metformin + Sitagliptin | Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice. |
| FG001 | Metformin + Sulfonylurea | Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| Sulfonylurea | Drug |
|
| Antihyperglycemic Medication | Drug |
|
| FG002 | Sitagliptin +/- Other Antihyperglycemic Medication | Participants taking sitagliptin +/- other antihyperglycemic medications (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof. |
| COMPLETED |
|
| NOT COMPLETED |
|
Baseline gender data is missing for 8 participants in the Metformin + Sitagliptin group.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Metformin + Sitagliptin | Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice. |
| BG001 | Metformin + Sulfonylurea | Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride. |
| BG002 | Sitagliptin +/- Other Antihyperglycemic Medication | Participants taking sitagliptin +/- other antihyperglycemic medications (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof. |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex/Gender, Customized | Number | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Median Duration (in Months) of Initial Dual Therapy | The treatment maintenance duration corresponds to the treatment maintenance and persistence duration for dual therapy combining the same agents. Withdrawal of an agent, replacement of one agent by another or addition of a third agent is perceived as a change in treatment and, hence, the end of the treatment maintenance duration for dual therapy. | All eligible participants receiving dual therapy with metformin + sitagliptin or metformin + sulfonylurea. | Posted | Median | 95% Confidence Interval | months | Up to 3 years |
|
|
| ||||||||||||||||||||||||||||
| Primary | Percentage of Participants With Strict Changes in Initial Dual Therapy | Strict changes in dual therapy were defined as withdrawal of an agent, replacement of one agent by another, or the addition of a third agent. Changes in dose level were not considered strict changes. | All eligible participants receiving dual therapy metformin + sitagliptin or metformin + sulfonylurea. | Posted | Number | Percentage of Participants | Up to 3 years |
|
|
Up to 3 years
Population of participants receiving treatment with metformin + sitagliptin or metformin + sulfonylurea or sitagliptin +/- other antihyperglycemic medication.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Metformin + Sitagliptin | Participants taking metformin + sitagliptin as prescribed in routine clinical practice. | 68 | 1,874 | 0 | 1,874 | ||
| EG001 | Metformin + Sulfonylurea | Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride. | 35 | 733 | 0 | 733 | ||
| EG002 | Sitagliptin +/- Other Antihyperglycemic Medication | Participants taking sitagliptin +/- other antihyperglycemic medications (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof. | 66 | 846 | 0 | 846 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Acute Coronary Syndrome | Cardiac disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Angina pectoris | Cardiac disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Cardiac failure | Cardiac disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Cardiac failure acute | Cardiac disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Myocardial infarction | Cardiac disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Tachycardia | Cardiac disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Retinopathy | Eye disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Ascites | Gastrointestinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Gastritis Erosive | Gastrointestinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Inflammatory bowel disease | Gastrointestinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Intestinal infarction | Gastrointestinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Pancreatitis | Gastrointestinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Peritonitis | Gastrointestinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Death | General disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Gait disturbance | General disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| General physical health deterioration | General disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Malaise | General disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Cholecystitis acute | Hepatobiliary disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Hepatic cirrhosis | Hepatobiliary disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Heptatomegaly | Hepatobiliary disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Bronchopneumonia | Infections and infestations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Erysipelas | Infections and infestations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Lung infection | Infections and infestations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Paronychia | Infections and infestations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Septic shock | Infections and infestations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Tooth abscess | Infections and infestations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Viral pericarditis | Infections and infestations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Wound infection | Infections and infestations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Anaesthetic complication | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Dural tear | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Femoral neck fracture | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Fibula fracture | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Foot fracture | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Forearm fracture | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Lower limb fracture | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Open wound | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Overdose | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Pelvic fracture | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Rib fracture | Injury, poisoning and procedural complications | MedDRA 17.0 | Non-systematic Assessment |
| |
| Blood creatinine increased | Investigations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Blood culture positive | Investigations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Blood glucose increased | Investigations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Cardiac stress test | Investigations | MedDRA 17.0 | Non-systematic Assessment |
| |
| Anorexia | Metabolism and nutrition disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Diabetes mellitus inadequate control | Metabolism and nutrition disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Diabetic foot | Metabolism and nutrition disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Failure to thrive | Metabolism and nutrition disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Hypoglycaemic seizure | Metabolism and nutrition disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Metabolic acidosis | Metabolism and nutrition disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Bursitis | Musculoskeletal and connective tissue disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Rotator cuff syndrome | Musculoskeletal and connective tissue disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Bladder cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Bone neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Chronic lymphocytic leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Colon cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Colon cancer Stage 0 | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Endometrial cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Laryngeal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Lung adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Lung squamous cell carcinoma stage unspecified | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Malignant neoplasm of ampulla of vater | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Malignant peritoneal neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Metatases to bone | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Metatases to liver | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Metastasis | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Pancreatic carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Pleural mesothelioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Prostate cancer Stage III | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Rectal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Renal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
| |
| Cerebral haemorrhage | Nervous system disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Cerebrovascular accident | Nervous system disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Convulsion | Nervous system disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Haemorrhagic stroke | Nervous system disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Intracranial aneurysm | Nervous system disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Ischaemic stroke | Nervous system disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Sciatica | Nervous system disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Transient ischaemic attack | Nervous system disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Vascular dementia | Nervous system disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Pregnancy | Pregnancy, puerperium and perinatal conditions | MedDRA 17.0 | Non-systematic Assessment |
| |
| Completed Suicide | Psychiatric disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Diabetic Nephropathy | Renal and urinary disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Nephrolithiasis | Renal and urinary disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Renal colic | Renal and urinary disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Renal failure | Renal and urinary disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Renal failure acute | Renal and urinary disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Endometrial hyperplasia | Reproductive system and breast disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Metrorrhagia | Reproductive system and breast disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Acquired diaphragmatic eventration | Respiratory, thoracic and mediastinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Acute pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Lung disorder | Respiratory, thoracic and mediastinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Pulmonary fibrosis | Respiratory, thoracic and mediastinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Respiratory distress | Respiratory, thoracic and mediastinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Angioedema | Skin and subcutaneous tissue disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Skin ulcer | Skin and subcutaneous tissue disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Angioplasty | Surgical and medical procedures | MedDRA 17.0 | Non-systematic Assessment |
| |
| Arthrodesis | Surgical and medical procedures | MedDRA 17.0 | Non-systematic Assessment |
| |
| Diverticulectomy | Surgical and medical procedures | MedDRA 17.0 | Non-systematic Assessment |
| |
| Gastrectomy | Surgical and medical procedures | MedDRA 17.0 | Non-systematic Assessment |
| |
| Hospitalisation | Surgical and medical procedures | MedDRA 17.0 | Non-systematic Assessment |
| |
| Knee arthroplasty | Surgical and medical procedures | MedDRA 17.0 | Non-systematic Assessment |
| |
| Spinal laminectomy | Surgical and medical procedures | MedDRA 17.0 | Non-systematic Assessment |
| |
| Surgery | Surgical and medical procedures | MedDRA 17.0 | Non-systematic Assessment |
| |
| Toe amputation | Surgical and medical procedures | MedDRA 17.0 | Non-systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA 17.0 | Non-systematic Assessment |
| |
| Hepatic neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.0 | Non-systematic Assessment |
|
Not provided
The adverse events in this study were not systematically collected or assessed and therefore no direct comparison can be made between adverse events in the 3 study groups/arms.
Investigators cannot disclose any results without sponsor's agreement, only on request of French Health Authorities as per French law.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Senior Vice President, Global Clinical Development | Merck Sharp & Dohme Corp. | 1-800-672-6372 | ClinicalTrialsDisclosure@merck.com |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008687 | Metformin |
| D000068900 | Sitagliptin Phosphate |
| D013453 | Sulfonylurea Compounds |
| ID | Term |
|---|---|
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011719 | Pyrazines |
| D014508 | Urea |
| D000577 | Amides |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
Not provided
Not provided
| Male |
|
| Missing |
|
|